Celia Chicharro

Mrs. Celia Chicharro

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
ZVZoraida Verde
Zoraida Verde
LGLuz M. González
Luz M. González
CCCelia Chicharro
Celia Chicharro
LGLaura González-Rodríguez
Laura González-Rodríguez
NRNicolás Roberto Robles
Nicolás Roberto Robles
There is a pressing need for more precise biomarkers of chronic kidney disease (CKD). Plasma samples from 820 subjects [231 with CKD, 325 with end-stage kidney disease (ESKD) and 264 controls] were analyzed by liquid chromatography with tandem mass spectrometry (LC-MS/MS) to determine a metabolic profile of 28 amino acids (AAs) and biogenic amines to test their value as markers of CKD risk and progression. The kynurenine/tryptophan ratio showed the strongest correlation with estimated glomerular filtration rate values (coefficient = −0.731, p < 0.0001). Models created with orthogonal partial least squares-discriminant analysis (OPLS-DA) containing the metabolic signature showed a high goodness of fit and predictability for controls/CKD (R2X:0.73:R2Y:0.92:Q2:0.92, p < 0.0001) and lower values for CKD/ESKD (R2X:0.56:R2Y:0.59:Q2:0.55, p < 0.0001). Based on generated VIP scores, the most relevant markers for segregating samples into control/CKD and CKD/ESKD groups were citrulline (1.63) and tryptophan (1.47), respectively. ROC analysis showed that the addition of the metabolic profile to a model including CKD classic risk factors improved the AUC from 86.7% (83.6–89.9) to 100% (100–100) for CKD risk (p < 0.0001) and from 63.0% (58.2–67.8) to 96.5% (95.3–97.8) for the risk of progression from CKD to ESKD (p < 0.0001). Plasma concentrations of AAs and related amines may be useful as diagnostic biomarkers of kidney disease, both for CKD risk and for progression of CKD patients to ESKD.

10 October 2025 in European Journal of Internal Medicine
Verified
Journal Article
Open access
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
BCBárbara Cancho Castellano
Bárbara Cancho Castellano
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Cardiovascular (CV) complications are the leading cause of death in patients with chronic kidney disease (CKD). Endothelin-1 (ET-1), a potent vasoconstrictor involved in both renal and vascular dysfunction, may represent a promising biomarker for the disease. ET-1 plasma levels were quantified in 692 Spanish CKD patients (stages 1-5) and used to stratify individuals into three clusters (cluster 3 meaning highest concentrations). Associations with CKD progression, CVE, and all-cause mortality were assessed over a mean follow-up of 48.6 ± 27.4 months using linear mixed-effects models and Cox regression analyses adjusted for conventional risk factors. ET-1 levels increased with CKD severity (mean±SD: 1.65 ± 0.71 pg/mL for stages 1-2; 1.82 ± 0.71 pg/mL for stage 3; 2.39 ± 1.08 pg/mL for stages 4-5; p < 0.001). Higher ET-1 levels were independently associated with accelerated eGFR decline over 3 years (β = -12.64, p < 0.001 for cluster 2; and β = -11.71, p = 0.034 for cluster 3). Sixty-nine CVE (10.1 %) were recorded. Participants with higher ET-1 levels had significantly lower CV event-free survival [HR = 2.24 (1.12-4.45), p = 0.022, and HR = 2.50 (1.09-5.73), p = 0.03] for clusters 2 and 3, respectively. ET-1 also predicted all-cause mortality (p < 0.001) although the association lost significance after adjusting for age. Random forest models for CV risk and all-cause mortality including the ET-1 cluster produced C-indices of 0.835 and 0.837, respectively. Elevated ET-1 levels are independently associated with both CKD progression and CV complications. ET-1 may serve as a dual biomarker for renal deterioration and CV risk, potentially improving clinical stratification in CKD management.

27 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LGLaura González-Rodríguez
Laura González-Rodríguez
MAManuel Martí Antonio
Manuel Martí Antonio
VAVirginia Diaz Acevedo
Virginia Diaz Acevedo
SMSonia Mota-Zamorano
Sonia Mota-Zamorano
CCCelia Chicharro
Celia Chicharro
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
Background: Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. Methods: In 579 CKD patients, plasma FGF19 and β-Klotho concentrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1, and FGFR4 genes were analyzed. Results: Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR = 2.97 (1.12–7.92), p = 0.029]. Two genetic variants also showed independent associations: FGFR1 rs2288696 (protective) [HR = 0.51 (0.27–0.95), p = 0.029] and KLB rs2687971 (risk-increasing) [HR = 2.03 (0.97–4.27), p = 0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs, and traditional risk factors achieved good discriminative ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive importance comparable to diabetes and previous CV history. Conclusions: These results indicate that integrating FGF19-Klotho biomarkers with genetic information may improve CV risk prediction in CKD.

7 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Guillermo GervasiniGuillermo Gervasini
Guillermo Gervasini
ZVZoraida Verde
Zoraida Verde
LGLuz María González
Luz María González
CCCelia Chicharro
Celia Chicharro
LGLaura González-Rodríguez
Laura González-Rodríguez
NRNicolás Roberto Robles
Nicolás Roberto Robles
There is a pressing need for more precise biomarkers of chronic kidney disease (CKD). Plasma samples from 820 subjects [231 with CKD, 325 with end-stage kidney disease (ESKD) and 264 controls] were analyzed by LC-MS/MS to determine a metabolic profile of 28 aminoacids (AA) and biogenic amines to test their value as markers of CKD risk and progression. The Kynurenine/Tryptophan ratio showed the strongest correlation with estimated glomerular filtration rate values (coefficient=-0.731, P<0.0001). Models created with Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) containing the metabolic signature showed high goodness of fit and predictability for controls/CKD (R2X:0.73;R2Y:0.92;Q2:0.92) and lower for CDK/ESKD (R2X:0.56;R2Y:0.59;Q2:0.55). Based on generated VIP scores, the most relevant markers for segregating samples into control/CKD or CKD/ESKD groups were citrulline (1.67) and tryptophan (1.59), respectively. ROC analysis showed that the addition of the metabolic profile to a model including CKD classic risk factors improved AUC from 86.7% (83.6-89.9) to 100% (100-100) for CKD risk (P<0.0001), and from 63.0% (58.2-67.8) to 96.5% (95.3-97.8) for the risk of progression from CKD to ESKD (P<0.0001). Plasma concentrations of AA and related amines may be useful as diagnostic biomarkers of kidney disease, both for CKD risk and for progression of CKD patients to ESKD.

13 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
IEIsabel Erenas-Ondategui
Isabel Erenas-Ondategui
JGJulia Gomez-Castro
Julia Gomez-Castro
SHSandra Estepa Hernández
Sandra Estepa Hernández
CCCelia Chicharro
Celia Chicharro
RPRegina Peiro
Regina Peiro
ZVZoraida Verde
Zoraida Verde
Background/Objectives: Genetic variants, such as the µ-opioid receptor 1 (OPRM1) rs1799971 and the catechol-O-methyltransferase (COMT) rs4680, have been considered among the potential causes in the development of some chronic pain conditions. In this regard, there are controversial results regarding their roles in fibromyalgia (FM). We aimed to investigate whether the OPRM1 rs1799971 and COMT rs4680 polymorphisms are associated with the development of or susceptibility to FM, as well as their potential association with syndrome characteristic variables, in a sample of the Spanish population with and without FM. Methods: The present study analysed COMT Val158Met and OPRM1 Asn40Asp genetic variants in 311 FM patients (301 women and 10 men) and 135 non-FM participants (120 women and 15 men). In addition to clinical variables, widespread pain index (WPI), symptom severity scale (SSS) (fatigue, rest quality, and cognitive symptoms), pain, stress episodes, and Borg scale were collected. Results: The main results indicate that women carrying the Val/Val genotype (i.e., high COMT activity) exhibited significantly lower levels of fatigue, cognitive impairment, and total SSS than heterozygote carriers. In addition, Met allele carriers (i.e., lower COMT activity) showed higher probabilities of suffering a stress episode and higher levels of exertion during daily activities. Conclusions: The present research suggests a link between dopaminergic dysfunction and exacerbated, frequently described symptoms in female FM patients. Although further research with wider genetic variants and recruited patients is needed, these results point out the necessity of considering gender as a separate category in chronic pain studies.

16 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
CCCelia Chicharro
Celia Chicharro
PRPatricia Romero-Marco
Patricia Romero-Marco
LGLuz M. González
Luz M. González
LGLaura González-Rodríguez
Laura González-Rodríguez
LMLaura Mateo-Vivaracho
Laura Mateo-Vivaracho
ZVZoraida Verde
Zoraida Verde
Background: Nutritional biomarkers are essential for assessing the impact of dietary interventions on health. Amino Acids (AA) serve as potential biomarkers due to their role in metabolic pathways, although the influence of combining macronutrients on AA metabolism remains unclear. Objective: This study aims to evaluate the effects of combining macronutrients (fat, protein, and fiber) on AA metabolism. Methods: A dietary intervention was conducted with 41 participants who were assigned to two groups: the Protein Fat (PF) group and the Protein Fat and Fiber (PFF) group. AA concentration was measured using LC-MS/MS. Results: Our findings indicated that combining macronutrients reduced plasma levels of AA with statistically significant differences between the two diets (p < 0.05 for EAA and BCAA; p < 0,01 for NEAA and AAA). Metabolic profile analysis showed differences between the groups, especially at 55 days (55 D) (R2X: 0.749; R2Y: 0.589; Q2: 0.582, p < 0.001) and 98 days (98 D) (R2X: 0.886; R2Y: 0.7; Q2: 0.605, p < 0.001). Five metabolites (leucine, asparagine, alanine, cysteine, and creatine) were the most influential factors in group differentiation (VIP score), with values ranging between 1.04 and 1.75. Conclusions: The combination of macronutrients led to a significant reduction in plasma amino acids and amines in the PFF group, with recovery post-intervention. These findings highlight the possibility that these metabolites are related to different health statuses.